Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 166 AL 180

The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease

Mesiti F, Chavarria D, Gaspar A, Alcaro S, Borges F.

Eur J Med Chem. 2019 Nov 1;181:111572. doi: 10.1016/j.ejmech.2019.111572. Epub 2019 Aug 1.

Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives

Lanzillotta C, Di Domenico F, Perluigi M, Butterfield DA.

CNS Drugs. 2019 Oct;33(10):957-969. doi: 10.1007/s40263-019-00658-8.

Herpes simplex virus type 1 and Alzheimer's disease: link and potential impact on treatment

Mancuso R, Sicurella M, Agostini S, Marconi P, Clerici M.

Expert Rev Anti Infect Ther. 2019 Sep;17(9):715-731. doi: 10.1080/14787210.2019.1656064. Epub 2019 Aug 23.

Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer's disease

Singh AK, Singh SK, Nandi MK, Mishra G, Maurya A, Rai A, Rai GK, Awasthi R, Sharma B, Kulkarni GT.

Cent Nerv Syst Agents Med Chem. 2019;19(3):154-170. doi: 10.2174/1871524919666190820160053.

Development of new treatments for Alzheimer's disease based on the modulation of translocator protein (TSPO)

Arbo BD, Ribeiro MF, Garcia-Segura LM.

Ageing Res Rev. 2019 Sep;54:100943. doi: 10.1016/j.arr.2019.100943. Epub 2019 Aug 17.

Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis

Blanco-Silvente L, Castells X, Garre-Olmo J, Vilalta-Franch J, Saez M, Barceló MA, Capellà D.

Eur J Clin Pharmacol. 2019 Dec;75(12):1659-1667. doi: 10.1007/s00228-019-02742-w. Epub 2019 Aug 21.

Management of oxidative stress and other pathologies in Alzheimer's disease

Simunkova M, Alwasel SH, Alhazza IM, Jomova K, Kollar V, Rusko M, Valko M.

Arch Toxicol. 2019 Sep;93(9):2491-2513. doi: 10.1007/s00204-019-02538-y. Epub 2019 Aug 22.

ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease

Alavez-Rubio JS, Juarez-Cedillo T.

Curr Alzheimer Res. 2019;16(8):699-709. doi: 10.2174/1567205016666190823125245.

Neuropeptides in Alzheimer's Disease: An Update

Petrella C, Di Certo MG, Barbato C, Gabanella F, Ralli M, Greco A, Possenti R, Severini C.

Curr Alzheimer Res. 2019;16(6):544-558. doi: 10.2174/1567205016666190503152555.

Nanomedicine for the Treatment of Alzheimer's Disease

Formicola B, Cox A, Dal Magro R, Masserini M, Re F.

J Biomed Nanotechnol. 2019 Oct 1;15(10):1997-2024. doi: 10.1166/jbn.2019.2837.

Peripheral blood DNA methylation differences in twin pairs discordant for Alzheimer's disease

Konki M, Malonzo M, Karlsson IK, Lindgren N, Ghimire B, Smolander J, Scheinin NM, Ollikainen M, Laiho A, Elo LL, Lönnberg T, Röyttä M, Pedersen NL, Kaprio J, Lähdesmäki H, Rinne JO, Lund RJ.

Clin Epigenetics. 2019 Sep 2;11(1):130. doi: 10.1186/s13148-019-0729-7.

Rebalancing metal dyshomeostasis for Alzheimer's disease therapy

Yang GJ, Liu H, Ma DL, Leung CH.

J Biol Inorg Chem. 2019 Dec;24(8):1159-1170. doi: 10.1007/s00775-019-01712-y. Epub 2019 Sep 5.

Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease

Liu L, Xu H, Ding S, Wang D, Song G, Huang X.

Brain Res Bull. 2019 Nov;153:223-231. doi: 10.1016/j.brainresbull.2019.09.001. Epub 2019 Sep 4.

Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease

Lee HE, Lim D, Lee JY, Lim SM, Pae AN.

Future Med Chem. 2019 Aug;11(15):1845-1848. doi: 10.4155/fmc-2019-0151.

Phosphodiesterase inhibitors say NO to Alzheimer's disease

Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M, Tewari D, Argüelles S, Mehrzadi S, Hosseinzadeh A, D'onofrio G, Orhan IE, Sureda A, Xu S, Momtaz S, Farzaei MH.

Food Chem Toxicol. 2019 Dec;134:110822. doi: 10.1016/j.fct.2019.110822. Epub 2019 Sep 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias